The lower rate of CR expected in the more aggressive FLT3-mutated AML may also predispose one to IFD [14,15] but in our study, 72.8% of patients treated with chemotherapy + midostaurin achieved a CR after first induction, as opposed to 59% in the midostaurin arm of the RATIFY study. Here, FLT3 is linked to acute myeloid leukemia.